Your Cart Is Empty!
FirstWord Pharma supplies global news and intelligence to the pharmaceutical industry. The service provides the top industry news stories on a daily basis in a format that is quick and easy to access so that users can always be in-the-know about the latest news and developments in their industry.
Why FirstWord Pharma?
Cover all the angles with extensive Pharma industry news coverage
Get breaking pharmaceutical industry news online, covering news in all major areas e.g corporate affairs, mergers and acquisitions, marketing and sales, regulatory affairs, licensing, clinical research / R&D, medical affairs and medical meetings.
Catch the latest news with daily editor “Top Story” news summaries
Read “Top Story” news summaries from the FirstWord Pharma team of editors, with related news coverage reviewed, validated, tagged, edited and fully referenced. Draw from over 500 Pharma/Biotech news and journal stories/abstracts summarised so you don’t have to.
View selected additional content through easy-to-use topic categories
Get access to selected additional news content compiled by FirstWord Pharma, including:
Company news – reporting on 3,500+ companies
Condition news – reporting on 120 medical conditions
Product news – reporting on over 10,000 products from early-stage clinical development to lifecycle extension strategies.
Regulatory market and agency news – over 120 regulatory bodies in dozens of world markets
Therapeutic category news – reporting across 32 therapeutic areas
Medical meeting news - editorial highlights from 100+ medical meetings delivered within hours of the presentations taking place
The "most popular" news items from the last 24 hours, the last 7 days, or the last 30 days.
"StoryWatch" news items from hot topic areas (e.g Pharma and Social Media).
Go global. Get all your news in one source.
Coverage from 15+ world markets including US, EU, Japan, Brazil, India, and China.
About FirstWord Pharma PLUS
FirstWord Pharma PLUS combines the coverage of an in-depth pharmaceutical industry news and intelligence service with the convenience of user customisation. Users enjoy full access to the FirstWord Pharma news service, including all news stories, both past and present, with customisation tools to enable them to filter in or filter out what’s most relevant to them.
Your customers need and demand more from you today. Key Account Management (KAM) is the model designed to deliver it. But as prescribing decisions become increasingly complicated, complexity that is compounded by the growth of integrated care net Learn More$595.00
Accountable Care Organizations are set to transform the US health market, establishing efficiencies in patient care and physician working. While their impact to date is limited, ACOs ever widening remit as key funding and decision-making stakehold Learn More$695.00
How to collect and interpret the real world data that supports your brand and improves patient outcomes
Real world data is being employed across a wide spectrum of pharma’s activities and is proving itself in a range of research, cli Learn More$695.00
Immunotherapies are about to transform HNSCC treatment. Can one brand corner the market? Key opinion leaders (KOLs) say immunotherapies will transform the head and neck squamous cell carcinoma (HNSCC) landscape. But until Phase III trial results a Learn More$7,900.00
The pay for performance agenda gathers pace as US payers rebel at the cost of drugs. Pharma is in the firing line as fundamental change sweeps across the US health delivery sector. Driven by unsustainable growth in drug costs, health payers want Learn More$695.00
In this update KOLs reflect on the promising Phase Ib data for Roche’s monoclonal antibody (mAb), atezolizumab, in combination with nab-paclitaxel for patients with metastatic triple- negative breast cancer (mTNBC); the US Food and Drug Administrat Learn More$995.00
Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of moderate to severe plaque psoriasis. Topics covered include opinions about ixekizumab (Eli Lilly) and if safety concerns related to anti-IL-17 mAbs Learn More$995.00